 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who''s Online | |
There are currently, 140 guest(s) and 49 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | Research: Long-Term Antibiotic Use Raises Cold and Flu Risk |
 Recent interest in antibiotics as a potential treatment for MS have brought this class of therapeutics into our sphere of interest. A new study shows that acne sufferers, a group that often uses long-term antibiotics of the tetracycline family have an elevated risk for developing upper respiratory tract infections.
More specifically, for patients using topical or internal antibiotics for longer than six weeks, the risk for an infection was two times higher than for non-antibiotic controls. This is relevant for MS''ers using antibiotics as it shows the potential risks of long-term use of the drugs, particularly with respect to giving rise to antibiotic-resistant strains whose activity is theorized to pave the way for other opportunistic viral infections, such as influenza.
For more information, click "read more"...
|
|
|
Posted by Administrator on Tuesday, September 20 @ 04:16:59 CDT (6392 reads)
(Read More... | 1115 bytes more | Research | Score: 0)
|
|
|
| Research: Study on Chlamydia Pneumonia Infection in Multiple Sclerosis Patients |
|
An interesting new study by the pro-antibiotic researchers Sriram et. al. on the presence, or lack thereof, of the bacterium Chlamydia Pneumoniae (CPn) in the central nervous system of multiple sclerosis patients. While not providing overwhelming evidence of CPn infection in MS''ers versus healthy controls, they did find strong indications that a certain subset of MS patients have CPn infections.
"To examine a possible relationship between Chlamydia pneumoniae infection and multiple sclerosis (MS), we undertook an immunohistochemical (IHC), molecular, and ultrastructural comparison of central nervous system (CNS) tissue and cerebrospinal fluid (CSF) sediment from patients with MS and control individuals with other neurological diseases (ONDs)...
Results of studies using these different approaches support our suspicion of the presence of chlamydial organisms in the CNS, in a subset of patients with MS."
Please click "read more" for the full abstract...
|
|
|
Posted by Administrator on Monday, September 12 @ 04:10:03 CDT (7017 reads)
(Read More... | 1256 bytes more | Research | Score: 3.5)
|
|
|
| Non-Antibacterial Tetracylines Protective in Animal MS Models |
|
Here''s a very interesting study that could possibly explain just how antibiotics such as minocycline might help with MS-- and the result is surprising. If you extrapolate from this study (which is performed on a mouse model-- in other words, no guarantee that it translates directly to humans), the anti-bacterial activity is NOT the reason behind antibiotic''s beneficial effects. Instead, some of the non-anti-bacterial components are somehow neuroprotective... Furthermore, Serono (maker of Rebif) announced that they are investing in this set of non-antibacterial antibiotics with the mission to bring them to market as an oral MS treatment. With this move, Serono joins Teva (who is funding research on laquinimod) in investing in oral therapies.
"...A previous clinical study directed by Dr. Luanne Metz at the University of Calgary has demonstrated disease protection in MS patients
treated with minocycline. Unfortunately, long-term treatment with minocycline or any other broad-spectrum antibiotic causes many patients to experience intolerability related to antibiotic side effects. In today''s presentation, Paratek will report that three non-antibacterial tetracycline compounds, with different structures, demonstrated activity in reducing limb paralysis in the preclinical EAE (Experimental Autoimmune Encephalomyelitis) model of MS. These compounds have no detectable antibacterial activity...
"The clinical research community has long regarded a pill for MS as an ultimate goal, but so far attempts to develop a safe,
feasible, orally available drug candidate have failed. Our team has
successfully modified the tetracycline molecule, keeping the core structure
that confers anti-MS activity while removing portions of the molecule with
antibacterial effects.
Click "read more" for the full story...
|
|
|
Posted by Administrator on Wednesday, October 27 @ 03:21:54 CDT (4147 reads)
(Read More... | 7721 bytes more | Score: 4.28)
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Survey | |
| Big Story of Today | |
|
There isn't a Biggest Story for Today, yet. | |
| Old Articles | |
|
There isn't content right now for this block. | |
| Latest Forum Posts | |
| Information | |
|
This site is privately funded by individuals interested in fighting multiple sclerosis.
There are no corporate grants, medical center affiliations, or overbearing advertisements, providing a truly independent online community for MS.
Note that all medical decisions should be made with the consent of your doctor. | |
|
|
